PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

5276 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-01

Study Completion Date

2029-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An investigator-initiated, prospective, multicenter, randomized, double-blind, placebo-controlled trial comparing the 1-year incidence of stroke in patients with AIS or TIA within 7 days who are treated with either placebo or Recaticimab.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis

NCT06902740

Intracranial Atherosclerosis Intracranial Artery Stenosis Atherosclerotic Plaque

RECRUITING PHASE4

Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome

NCT05397405

Intracranial Artery Stenosis

RECRUITING NA

A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging

NCT00633022

Atherosclerosis

COMPLETED PHASE2

Evolocumab Added to Statin Therapy in Symptomatic Intracranial Atherosclerotic Stenosis (EAST-ICAS)

NCT05741086

Stroke Patients With Symptomatic Intracranial Atherosclerotic Stenosis

UNKNOWN PHASE3

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

NCT03507374

Stroke Intracranial Atherosclerosis Intraplaque Hemorrhage

TERMINATED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an investigator-initiated, prospective, multicenter, randomized, double-blind, placebo-controlled trial to determine the efficacy of Recaticimab (PCSK9 inhibitor) administered within 7 days of symptom onset in patients with symptomatic intracranial atherosclerotic stenosis (sICAS) in reducing incident stroke within 1 year.

Study intervention: (1) Participants in the intervention group will receive Recaticimab 300mg subcutaneous Q8W for 1 year. (2) Participants in the control group will receive matched placebo subcutaneous Q8W for 1 year. All participants will receive best medical management (BMM), including intensive statins treatment and dual antiplatelet therapy.

A total of 5276 participants are anticipated to be recruited for this study. Eligible participants will be 1:1 randomly assigned to receive Recaticimab or placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Symptomatic Intracranial Atherosclerotic Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Recaticimab group

Group Type EXPERIMENTAL

Recaticimab

Intervention Type DRUG

Recaticimab 300mg subcutaneous Q8W for 1 year.

Placebo group

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matched placebo subcutaneous Q8W for 1 year.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Recaticimab

Recaticimab 300mg subcutaneous Q8W for 1 year.

Intervention Type DRUG

Placebo

Matched placebo subcutaneous Q8W for 1 year.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Aged ≥30 years and ≤80 years.

Patients aged between 30 to 49 are required to meet at least one of the following criteria:

1. Insulin dependent diabetes for at least 15 years.
2. At least 2 of the following atherosclerotic risk factors: hypertension (BP \> 140/90 or on antihypertensive therapy); dyslipidemia (LDL \> 130 mg /dL or HDL \< 40 mg/dL or fasting triglycerides \> 150 mg/dL or on lipid lowering therapy); smoking; non-insulin dependent diabetes or insulin dependent diabetes of less than 15 years duration; family history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in parent or sibling who was \< 55 years of age for men or \< 65 for women at the time of the event.
3. History of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease.
4. Any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic.
5. Aortic arch atheroma documented by non-invasive vascular imaging or catheter angiography vi. any aortic aneurysm documented by non-invasive vascular imaging or catheter angiography that is considered atherosclerotic.

2\. Diagnosed with acute ischemic stroke or moderate-to-high risk transient ischemic attack (ABCD2 score ≥4).

3\. CTA or DSA confirmed intracranial atherosclerotic stenosis \>50%, which was responsible for the incident.

4\. The time from symptom onset to initiation of study treatment is within 7 days.

5\. Signed informed consent.

Exclusion Criteria

1. Baseline NIHSS ≥26.
2. Suspected cardiogenic ischemic cerebrovascular diseases (e.g., combined with atrial fibrillation, heart valve prosthesis, atrial myxoma, endocarditis, etc.).
3. Source of symptoms is possible related to ipsilateral carotid disease.
4. Other ischemic cerebrovascular diseases with specific causes (e.g., aortic dissection, vasculitis, vascular malformation, etc.).
5. Non-cerebral vascular disease (e.g., intracranial tumors, multiple sclerosis).
6. Hemorrhagic stroke or hemorrhagic transformation of cerebral infarction before randomization.
7. Pre-existing contraindications of using PCSK9 inhibitors.
8. Use of any PCSK9 inhibitors within the past 3 months.
9. Pregnant or childbearing-age women who have no effective contraceptives or positive pregnancy test records.
10. Patients who are participating in other trials.
11. Hepatic or renal dysfunction, defined as AST and/or ALT \>3ULN，eGFR\<30mL/min, or Crea \>220μmol/L (2.5mg/dL).
12. Uncontrolled hypertension defined as systolic blood pressure (BP) \>220mmHg or diastolic BP \>120mmHg.
13. Life expectancy is less than 1 year due to severe non-cardiovascular disease.
14. Angioplasty or stenting procedure is planned before randomization.
15. Unable to finish the follow-up visit due to geographical factor or other reasons (e.g., dementia, alcoholism, substance abuse, severe mental disease, etc.)

Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No